A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma-Reference-Cited by-同舟云学术

A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma

Published:2011-05-31 Issue:7 Volume:86 Page:573-578
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am. J. Hematol.

Author:

Ghobrial Irene M.,Munshi Nikhil C.,Harris Brianna N.,Shi Peipei,Porter Nichole M.,Schlossman Robert L.,Laubach Jacob P.,Anderson Kenneth C.,Desaiah Durisala,Myrand Scott P.,Wooldridge James E.,Richardson Paul G.,Abonour Rafat

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ajh.22048/fullpdf

Reference16 articles.

1. Cancer statistics, 2010;Jemal;CA Cancer J Clin,2010

2. Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma;Badros;Clin Cancer Res,2009

3. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: Final time-to-event results of the APEX trial;Richardson;Blood,2007

4. Clinical course of patients with relapsed multiple myeloma;Kumar;Mayo Clin Proc,2004

5. Multiple myeloma;Kyle;N Engl J Med,2004

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging protein kinase inhibitors for the treatment of multiple myeloma;Expert Opinion on Emerging Drugs;2019-07-03

2. Potentials of PKC in Cancer Progression and Anticancer Drug Development;Current Drug Discovery Technologies;2019-06-24

3. Immunoproteasome-selective and non-selective inhibitors: A promising approach for the treatment of multiple myeloma;Pharmacology & Therapeutics;2018-02

4. Bortezomib pharmacokinetics in tumor response and peripheral neuropathy in multiple myeloma patients receiving bortezomib-containing therapy;Anti-Cancer Drugs;2017-07

5. Effect of Lipoic Acid on the Biochemical Mechanisms of Resistance to Bortezomib in SH-SY5Y Neuroblastoma Cells;Molecular Neurobiology;2017-05-11